Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T19:49:26.565Z.
Calculation as of: 2026-10-06T19:49:26.565Z.
Quote observation: 2026-10-06T19:45:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: bc1f4c18f19876ab16fbc38bb33c2f59d02ebf5b777874ee4386cd5e587f8fe3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$612.14M
Price/FCF Ratio
N/A
TTM Avg
3847.94
3Y Avg
3847.94
5Y Avg
3847.94
Market Cap
$631.35M
Price/FCF Ratio
19.39
TTM Avg
44.71
3Y Avg
44.71
5Y Avg
30.89
Market Cap
$594.22M
Price/FCF Ratio
3.20
TTM Avg
7.03
3Y Avg
5.99
5Y Avg
6.65
Market Cap
$593.12M
Price/FCF Ratio
1167.57
TTM Avg
742.47
3Y Avg
742.47
5Y Avg
415.90
Market Cap
$583.77M
Price/FCF Ratio
N/A
TTM Avg
59.55
3Y Avg
26.45
5Y Avg
31.22
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SOPHiA GENETICS S.A. (SOPH) | $623.06M | N/A | N/A | N/A | N/A |
| OmniAb, Inc. (OABI)vs › | $619.76M | N/A | 697.87 | 748.88 | 748.88 |
| Climb Bio, Inc. (CLYM)vs › | $612.14M | N/A | 3847.94 | 3847.94 | 3847.94 |
| Aura Biosciences, Inc. (AURA)vs › | $632.49M | N/A | N/A | N/A | N/A |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $631.35M | 19.39 | 44.71 | 44.71 | 30.89 |
| Prime Medicine, Inc. (PRME)vs › | $633.06M | N/A | N/A | N/A | N/A |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $594.22M | 3.20 | 7.03 | 5.99 | 6.65 |
| AngioDynamics, Inc. (ANGO)vs › | $593.12M | 1167.57 | 742.47 | 742.47 | 415.90 |
| Fulgent Genetics, Inc. (FLGT)vs › | $583.77M | N/A | 59.55 | 26.45 | 31.22 |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $657.01M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
